Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.30 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | UTRN | P46939 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19960310 | 1.00 | MEN1 (0.30) | MEN1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL19960315 | 1.00 | MEN1 (0.30) | MEN1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL19960304 | 0.97 | MAPT (0.32) | MEN1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL19960183 | 0.96 | — | — | |
| SCHEMBL19960332 | 0.95 | CYP2C9 (0.34) | MAPTCYP2C9 | |
| SCHEMBL19960308 | 0.95 | — | — | |
| SCHEMBL19960317 | 0.94 | — | — | |
| SCHEMBL19960312 | 0.94 | — | — | |
| SCHEMBL19960090 | 0.94 | MEN1 (0.30) | MEN1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL19960055 | 0.93 | KMT2A (0.33) | MEN1CYP1A2CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | MEN1 885/4885CYP1A2 209/4885CYP2D6 444/4885 |
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | MEN1 885/4885CYP1A2 209/4885CYP2D6 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.